Last reviewed · How we verify

Varespladib intravenous form

Ophirex, Inc. · Phase 2 active Small molecule

Varespladib intravenous form is a Small molecule drug developed by Ophirex, Inc.. It is currently in Phase 2 development. Also known as: LY315920.

Varespladib is an investigational broad-spectrum antidote for snakebite, developed by Ophirex, Inc. It has completed a Phase 2 trial and shows promise in neutralizing venom toxins. The drug is a first-in-class small molecule inhibitor of secretory phospholipase A2 (sPLA2).

At a glance

Generic nameVarespladib intravenous form
Also known asLY315920
SponsorOphirex, Inc.
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Varespladib intravenous form

What is Varespladib intravenous form?

Varespladib intravenous form is a Small molecule drug developed by Ophirex, Inc..

Who makes Varespladib intravenous form?

Varespladib intravenous form is developed by Ophirex, Inc. (see full Ophirex, Inc. pipeline at /company/ophirex-inc).

Is Varespladib intravenous form also known as anything else?

Varespladib intravenous form is also known as LY315920.

What development phase is Varespladib intravenous form in?

Varespladib intravenous form is in Phase 2.

Related